For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

Lung cancer is the leading cause of cancer death in Canada and a significant cause of
morbidity for patients and their loved ones. There have been rapid advances in preventing …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …